The aim of the study is to determine the efficacy and safety of treatment with the drug eplerenone in patients with chronic central serous chorioretinopathy.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
28
Semmelweis University, Department of Ophthalmology
Budapest, Hungary
Resolution of sub-retinal fluid measured by optical coherence tomography (OCT).
Time frame: 6 months
Number of Participants with Adverse Events as a Measure of Safety and Tolerability.
Time frame: 3 months
Changes in macular volume at baseline, during and after the treatment with eplerenone.
Time frame: 6 months
Changes in visual acuity at baseline measured on Early Treatment of Diabetic Retinopathy Study (ETDRS) chart, during and after the treatment with eplerenone.
Time frame: 6 months
Changes in choroideal thickness at baseline measured by OCT, during and after the treatment with eplerenone in both eyes.
Time frame: 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.